National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting, 28634-28635 [2021-11211]
Download as PDF
<![CDATA[
28634
Federal Register / Vol. 86, No. 101 / Thursday, May 27, 2021 / Notices
plans and instruments, submit
comments in writing, or request more
information on the proposed project,
contact: Ms. Mikia P. Currie, Office of
Policy for Extramural Research
Administration, 6705 Rockledge Drive,
Suite 350, Bethesda, Maryland 20892, or
call a non-toll-free number 301–435–
0941 or Email your request, including
your address to
ProjectClearanceBranch@mail.nih.gov.
Formal requests for additional plans and
instruments must be requested in
writing.
SUPPLEMENTARY INFORMATION: Section
3506(c)(2)(A) of the Paperwork
Reduction Act of 1995 requires: Written
comments and/or suggestions from the
public and affected agencies are invited
to address one or more of the following
points: (1) The necessity and utility of
the proposed information collection for
the proper performance of the agency’s
functions; (2) the accuracy of the
estimated burden; (3) ways to enhance
the quality, utility, and clarity of the
information to be collected; and (4) the
use of automated collection techniques
or other forms of information
technology to minimize the information
collection burden.
Title of the Collection: Audience
Feedback to Inform Ongoing Messaging
and Strategies for ‘‘Combat COVID’’
Type of Collection: Emergency.
OMB No. 0925–NEW—Federal COVID
Response
Abstract: The Federal COVID
Response (FCR) Team is a cross-agency
resources. Because the COVID–19
treatment landscape continues to evolve
and audience needs continue to change,
it is critical for the FCR Team to collect
routine feedback from the general public
(especially from groups who have not
historically been well-represented in
clinical trials) and healthcare providers
to identify these evolving needs. By
understanding evolving needs, the FCR
team will be able to properly develop
and broadly disseminate relevant
COVID–19 treatment and ACTIV
clinical trial resources. This effort will
require ongoing data collection over the
next 20 months (through the end of
December 2022).
Data collected through this effort will
be used to inform the development and
broad dissemination of Combat COVID
resources, including new or enhanced
messages, materials and/or web pages
(combatcovid.hhs.gov).
The team will employ two strategies
to collect this routine audience
feedback:
1. DATA COLLECTION STRATEGY 1:
Monthly 60-minute virtual audience
feedback teams sessions (focus groups,
in-depth interviews, online bulletin
boards) for rapid testing of new Combat
COVID messages, concepts, ideas,
resources, web pages, and materials.
2. DATA COLLECTION STRATEGY 2:
15-minute custom web surveys to
understand target audiences’ needs and
awareness of Combat COVID over time,
and to inform ongoing messages and
strategies.
partnership that includes the U.S.
Department of Health and Human
Services (HHS), including the National
Institutes of Health (NIH) Office of the
Director, Centers for Disease Control
and Prevention (CDC), the U.S. Food
and Drug Administration (FDA), the
Biomedical Advanced Research and
Development Authority (BARDA), and
the U.S. Department of Defense (DOD).
The FCR Team oversees the ‘‘Combat
COVID’’ initiative—a multifaceted effort
to provide the general public and
healthcare providers with the latest
evidence-based information on COVID–
19 treatments and the Accelerating
COVID–19 Therapeutic Interventions
and Vaccines (ACTIV) clinical trials
(including the combatcovid.hhs.gov
website). The NIH is especially
interested in recruiting participants
from groups who have historically been
underrepresented in clinical trials.
Together with their contractor, the FCR
Team is working to:
• Address participation barriers and
raise awareness of ACTIV clinical trials,
and
• Ensure the general public’s and
health care provider’s needs are met as
it pertains to evidence-based
information on these trials.
The purpose of the information
collection is to collect routine feedback
from the Combat COVID Initiative’s two
target audiences (the general public and
healthcare providers) to identify
evolving needs and better disseminate
relevant information relates to COVID–
19 treatment and ACTIV clinical trial
ESTIMATED ANNUALIZED BURDEN TABLE
Number of
respondents
Type of respondent
Total burden
hours
Consumer Audience Feedback Team Screener (Attachment 1) ....................
HCP Audience Feedback Team Screener (Attachment 2) .............................
Consumer Audience Feedback Activity (Attachments 3 & 5) .........................
HCP Audience Feedback Activity (Attachments 4 & 5) ..................................
Benchmark & Follow-Up Web Surveys—Consumer Audience (Attachment
6) ..................................................................................................................
Benchmark & Follow-Up Web Survey—HCP Audience (Attachment 6) .........
120
40
60
20
1
1
12
12
5/60
5/60
1
1
10
3
720
240
2,000
300
5
5
15/60
15/60
2,500
375
Total ..........................................................................................................
2,540
12,620
........................
3848
Dated: May 20, 2021.
Lawrence A. Tabak,
Principal Deputy Director, National Institutes
of Health.
jbell on DSKJLSW7X2PROD with NOTICES
Average
burden per
response
(in hours)
Number
responses per
respondent
[FR Doc. 2021–11255 Filed 5–26–21; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
VerDate Sep<11>2014
17:29 May 26, 2021
Jkt 253001
PO 00000
Frm 00110
Fmt 4703
Sfmt 4703
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
E:\FR\FM\27MYN1.SGM
27MYN1
Federal Register / Vol. 86, No. 101 / Thursday, May 27, 2021 / Notices
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; Cohort Studies To Improve
Our Understanding of Influenza Immunity,
Vaccine Response and Effectiveness in Older
Adults (65 years and older) (U01 Clinical
Trial Not Allowed).
Date: July 9, 2021.
Time: 10:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3G42,
Rockville, MD 20892 (Virtual Meeting).
Contact Person: Sandip Bhattacharyya,
Ph.D., Scientific Review Officer, Scientific
Review Program, Division of Extramural
Activities, National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3G43,
Rockville, MD 20852, (240) 292–0189,
sandip.bhattacharyya@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: May 21, 2021.
Tyeshia M. Roberson,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2021–11211 Filed 5–26–21; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
jbell on DSKJLSW7X2PROD with NOTICES
Center for Scientific Review; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Small
Business: The Cancer Drug Development and
Therapeutics (CDDT).
Date: June 24–25, 2021.
Time: 9:00 a.m. to 8:00 p.m.
VerDate Sep<11>2014
17:29 May 26, 2021
Jkt 253001
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Lilia Topol, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 6192,
MSC 7804, Bethesda, MD 20892, 301–451–
0131, ltopol@mail.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Interventions and Mechanisms for
Addiction.
Date: June 28, 2021.
Time: 9:00 a.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Mark P. Rubert, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5218,
MSC 7852, Bethesda, MD 20892, 301–806–
6596, rubertm@csr.nih.gov.
Name of Committee: Population Sciences
and Epidemiology Integrated Review Group;
Cancer, Heart, and Sleep Epidemiology: A
Study Section.
Date: June 28–29, 2021.
Time: 9:00 a.m. to 8:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Denise Wiesch, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3138,
MSC 7770, Bethesda, MD 20892, (301) 437–
3478, wieschd@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Neurobehavior, Developmental
Psychopathology, Autism and Stress.
Date: June 29, 2021.
Time: 9:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Anna L. Riley, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3114,
MSC 7759, Bethesda, MD 20892, 301–435–
2889, rileyann@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Small
Business: Disease Prevention and
Management, Risk Reduction and Health
Behavior Change.
Date: June 29–30, 2021.
Time: 9:00 a.m. to 8:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Michael J. McQuestion,
Ph.D., Scientific Review Officer, Center for
PO 00000
Frm 00111
Fmt 4703
Sfmt 4703
28635
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3114,
MSC 7808, Bethesda, MD 20892, (301) 480–
1276, mike.mcquestion@nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; PAR Panel:
Cancer Health Disparities.
Date: June 29–30, 2021.
Time: 9:00 a.m. to 8:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Sulagna Banerjee, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Bethesda, MD
20892, 612.309.2479, sulagna.banerjee@
nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Fellowship:
Infectious Disease and Immunology B.
Date: June 29–30, 2021.
Time: 9:00 a.m. to 8:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Uma Basavanna, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Bethesda, MD
20892, 301–435–1199, uma.basavanna@
nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Small
Business: Cardiovascular and Surgical
Devices.
Date: June 29–30, 2021.
Time: 9:00 a.m. to 8:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Willard Wilson, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Bethesda, MD
20817, 301–867–5309, willard.wilson@
nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; The BloodBrain Barrier, Neurovascular Systems and
CNS Therapeutics.
Date: June 29, 2021.
Time: 10:00 a.m. to 7:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Linda MacArthur, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4187,
Bethesda, MD 20892, 301–537–9986,
macarthurlh@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; RFA Panel:
Nutrition for Precision Health.
Date: June 29, 2021.
Time: 1:00 p.m. to 5:00 p.m.
E:\FR\FM\27MYN1.SGM
27MYN1
]]>Agencies
[Federal Register Volume 86, Number 101 (Thursday, May 27, 2021)]
[Notices]
[Pages 28634-28635]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-11211]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and Infectious Diseases; Notice of
Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning
[[Page 28635]]
individuals associated with the grant applications, the disclosure of
which would constitute a clearly unwarranted invasion of personal
privacy.
Name of Committee: National Institute of Allergy and Infectious
Diseases Special Emphasis Panel; Cohort Studies To Improve Our
Understanding of Influenza Immunity, Vaccine Response and
Effectiveness in Older Adults (65 years and older) (U01 Clinical
Trial Not Allowed).
Date: July 9, 2021.
Time: 10:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institute of Allergy and Infectious Diseases,
National Institutes of Health, 5601 Fishers Lane, Room 3G42,
Rockville, MD 20892 (Virtual Meeting).
Contact Person: Sandip Bhattacharyya, Ph.D., Scientific Review
Officer, Scientific Review Program, Division of Extramural
Activities, National Institute of Allergy and Infectious Diseases,
National Institutes of Health, 5601 Fishers Lane, Room 3G43,
Rockville, MD 20852, (240) 292-0189, [email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.855,
Allergy, Immunology, and Transplantation Research; 93.856,
Microbiology and Infectious Diseases Research, National Institutes
of Health, HHS)
Dated: May 21, 2021.
Tyeshia M. Roberson,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2021-11211 Filed 5-26-21; 8:45 am]
BILLING CODE 4140-01-P
